Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.37 USD | -0.19% | -1.10% | -13.97% |
Valuation
Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|---|
Capitalization 1 | 8.519 | 7.657 | 35.94 | 6.878 | 7.33 | 6.345 | - | - |
Enterprise Value (EV) 1 | 8.519 | 7.657 | 35.94 | 6.878 | 7.33 | 6.345 | 6.345 | 6.345 |
P/E ratio | -0.52 x | -0.58 x | -1.43 x | -0.35 x | -0.38 x | -0.46 x | -0.49 x | -0.55 x |
Yield | - | - | - | - | - | - | - | - |
Capitalization / Revenue | - | - | - | - | - | - | - | - |
EV / Revenue | - | - | - | - | - | - | - | - |
EV / EBITDA | - | - | - | - | - | - | - | - |
EV / FCF | - | - | - | - | - | - | - | - |
FCF Yield | - | - | - | - | - | - | - | - |
Price to Book | - | - | - | - | - | - | - | - |
Nbr of stocks (in thousands) | 1,681 | 1,999 | 13,204 | 15,124 | 17,043 | 17,148 | - | - |
Reference price 2 | 5.069 | 3.830 | 2.722 | 0.4548 | 0.4301 | 0.3700 | 0.3700 | 0.3700 |
Announcement Date | 20/02/20 | 04/03/21 | 16/03/22 | 30/03/23 | 25/03/24 | - | - | - |
Income Statement Evolution (Annual data)
Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|---|
Net sales 1 | - | - | - | - | - | - | - | - |
EBITDA | - | - | - | - | - | - | - | - |
EBIT 1 | -15.66 | -10.16 | -14.27 | -21.58 | -21.43 | -28.57 | -34.29 | -37.13 |
Operating Margin | - | - | - | - | - | - | - | - |
Earnings before Tax (EBT) 1 | - | -10.12 | -14.27 | -21.11 | -19.99 | -28.57 | -34.29 | -37.13 |
Net income 1 | -16.08 | -12.56 | -23.19 | -19.68 | -18.35 | -28.57 | -34.29 | -37.13 |
Net margin | - | - | - | - | - | - | - | - |
EPS 2 | -9.800 | -6.600 | -1.900 | -1.310 | -1.140 | -0.8100 | -0.7600 | -0.6700 |
Free Cash Flow | - | - | - | - | - | - | - | - |
FCF margin | - | - | - | - | - | - | - | - |
FCF Conversion (EBITDA) | - | - | - | - | - | - | - | - |
FCF Conversion (Net income) | - | - | - | - | - | - | - | - |
Dividend per Share | - | - | - | - | - | - | - | - |
Announcement Date | 20/02/20 | 04/03/21 | 16/03/22 | 30/03/23 | 25/03/24 | - | - | - |
Income Statement Evolution (Quarterly data)
Fiscal Period: December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net sales 1 | - | - | - | - | - | - | - | - | - | - | - | - | - |
EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - |
EBIT 1 | -5.265 | - | -4.985 | -5.014 | -7.33 | -5.178 | -5.82 | -4.218 | -6.217 | -5.392 | -6.857 | -7.429 | -7.715 |
Operating Margin | - | - | - | - | - | - | - | - | - | - | - | - | - |
Earnings before Tax (EBT) 1 | -5.263 | - | -4.968 | -4.853 | -7.016 | -4.808 | -5.443 | -3.83 | -5.909 | -5.165 | -6.857 | -7.429 | -7.715 |
Net income 1 | -5.263 | - | -4.968 | -4.853 | -5.591 | -4.478 | -5.084 | -3.303 | -5.485 | -5.165 | -6.857 | -7.429 | -7.715 |
Net margin | - | - | - | - | - | - | - | - | - | - | - | - | - |
EPS 2 | -0.4000 | - | -0.3100 | -0.3300 | -0.3600 | -0.3000 | -0.3400 | -0.1900 | -0.3300 | -0.3000 | -0.1900 | -0.2100 | -0.2200 |
Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - |
Announcement Date | 16/03/22 | 16/05/22 | 11/08/22 | 10/11/22 | 30/03/23 | 11/05/23 | 08/08/23 | 13/11/23 | 25/03/24 | 07/05/24 | - | - | - |
Balance Sheet Analysis
Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|---|
Net Debt | - | - | - | - | - | - | - | - |
Net Cash position | - | - | - | - | - | - | - | - |
Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
Free Cash Flow | - | - | - | - | - | - | - | - |
ROE (net income / shareholders' equity) | - | - | - | - | - | - | - | - |
ROA (Net income/ Total Assets) | - | - | - | - | - | - | - | - |
Assets 1 | - | - | - | - | - | - | - | - |
Book Value Per Share | - | - | - | - | - | - | - | - |
Cash Flow per Share | - | - | - | - | - | - | - | - |
Capex | - | - | - | - | - | - | - | - |
Capex / Sales | - | - | - | - | - | - | - | - |
Announcement Date | 20/02/20 | 04/03/21 | 16/03/22 | 30/03/23 | 25/03/24 | - | - | - |
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-13.97% | 6.36M | |
+9.58% | 115B | |
+12.41% | 106B | |
-2.59% | 21.96B | |
-12.38% | 21.87B | |
-5.29% | 19.21B | |
-3.35% | 18.08B | |
-38.57% | 17.71B | |
+7.51% | 14.32B | |
+35.67% | 12.42B |
- Stock Market
- Equities
- TOVX Stock
- Financials Theriva Biologics, Inc.